The impact of rituximab infusion protocol on the long‐term outcome in anti‐MuSK myasthenia gravis
Annals of Clinical and Translational Neurology2018Vol. 5(6), pp. 710–716
Citations Over TimeTop 10% of 2018 papers
Elena Cortés‐Vicente, Ricard Rojas‐García, Jordi Díaz‐Manera, Luís Querol, Carlos Casasnovas, A. Guerrero-Solá, José Luís Muñoz-Blanco, José Eulalio Bárcena, Celedonio Márquez‐Infante, Julio Pardo, E Martínez-Fernández, Mercedes Usón, Pedro Oliva‐Nacarino, Teresa Sevilla, Isabel Illa
Abstract
This study provides class IV evidence that the 4 + 2 rituximab protocol has a lower clinical relapse rate and produces a more durable response than the 1 + 1 and 4 protocols in patients with MuSK MG.
Related Papers
- → Kaplan-Meier Curves, Log-Rank Tests, and Cox Regression for Time-to-Event Data(2021)49 cited
- [Kaplan-Meier analysis].(2005)
- → The statistical analysis of delayed effects in survival outcomes for immunotherapies. Estimation of time-delay and application of weighted log rank(2014)
- → Advances in rituximab treatment of refractory myasthenia gravis(2018)